AQST - Aquestive Therapeutics EPS misses by $0.04 misses on revenue revised FY20 guidance
Aquestive Therapeutics (AQST): Q3 GAAP EPS of -$0.49 misses by $0.04.Revenue of $8.3M (-33.1% Y/Y) misses by $0.42M.FY20 guidance: Total revenues of ~$42M-$46M vs consensus of $47.3M; Non-GAAP adjusted gross margins of ~70%-75%; Non-GAAP adjusted EBITDA loss of ~$38M-$42M; Cash burn of ~$45M-$50M.Shares -1.1%.Press Release
For further details see:
Aquestive Therapeutics EPS misses by $0.04, misses on revenue, revised FY20 guidance